A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/16 (2006.01) A61K 31/00 (2006.01) A61K 31/45 (2006.01) A61K 31/4545 (2006.01) A61K 45/06 (2006.01) A61P 31/18 (2006.01)
Patent
CA 2431919
This invention provides novel combination therapies comprising a CCR5 antagonist, or a pharmaceutically acceptable salt thereof, and a DP-178 polypeptide, or a pharmaceutically acceptable derivative thereof, for the treatment of HIV. The present combination permits a more tolerable treatment schedule by reducing the frequency of administration of a DP-178 polypeptide from twice daily subcutaneously to once daily or even just a few times per week.
L'invention concerne de nouvelles thérapies combinées contenant un antagoniste CCR5 ou un sel pharmaceutiquement acceptable de celui-ci et un polypeptide DP-178 ou un dérivé pharmaceutiquement acceptable de celui-ci afin de traiter le virus VIH. La présente combinaison permet une programmation de traitement plus tolérable en réduisant la fréquence d'administration d'un polypeptide DP-178, de deux fois par jour en sous-cutané à une fois par jour ou même jusqu'à quelques fois par semaine.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
Schering Corporation
LandOfFree
Ccr5 antagonist and dp-178 polypeptide for treating viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ccr5 antagonist and dp-178 polypeptide for treating viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ccr5 antagonist and dp-178 polypeptide for treating viral... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1821735